To date, GAL-binding studies have been used to deduce the presence of GALRs in human glioma, meningioma (21) and pituitary adenoma (29), but no receptor subtype has been identified at the cellular level, except indirectly from mRNA expression analyses in tissue extracts (21, 34). This evidence concerns the gene GAL and central nervous system cancer.